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ABSTRACT: 
GLYCATED NAIL PROTEIN AS AN INDICATOR OF LONG TERM GLYCEMIC 
CONTROL 
Cactus Lily Jeyaraj, Veena Juliette, R.Lalitha.     
Department of Biochemistry,Stanley Medical College and Hospital,           
Chennai-600 001, Tamil nadu, India. 
 Key words: Nail fructosamine, glycation, long term control                                                            
A study was conducted in Government Stanley Medical College and 
Hospital, in the Department of Biochemistry, titled glycated nail protein as an 
indicator of long term glycemic control . 
 A total of 70 individuals, 35 known diabetic patients and 35 healthy 
individuals were enrolled for the study. The patients were longitudinally followed 
up for three months to assess their glycemic status. 
The aim was to establish whether the nail fructosamine could be used to determine 
the glycemic status of the diabetic patients over the preceding three months 
which is the turnover time of the nail from root to the free edge. The 
Hemoglobin A1C estimation in the same patients at a same time was used to 
confirm the changes in the patient’s glycemic status and compared with nail 
fructosamine. A linear relationship was established after analysis of the 
results. ( p value 0.009 . A value of less than 0.5 is significant. 
There was also a significant difference of nail fructosamine between cases and 
controls ( p value 0.09) .The mean value of controls (2.18µmol/g equivalents 
of nail ) lie in the physiological range (2.0-2.5µmol/g)as reported by 
Goldsmith et al in 1985. 
The patients values determined initially and finally were above the physiological 
range (2.68 and 3.1µmol/g) 
The fasting blood glucose and serum fructosamine were also measured for 
assessing the blood glucose levels. These parameters on comparison with 
nail fructosamine showed linear relationship. 
No interference was done in the treatment schedule of the patients. 
The risk factors like positive family history, blood pressure, BMI, lipid profile 
were also analyzed. Results showed only moderate increase in risk factors among 
patients than in the controls. 
To conclude the nail fructosamine assay could be standardized for testing the 
levels of blood glucose over the previous three month’s duration. 
 The reference range in south Indian population needs to be established. 
The interference like drugs and other dietary substances which might react  
with nitrobluetetrazolium need to be studied and the procedure can be used as 
routine laboratory investigations to assess the blood glucose levels on long term 
basis. The method is cheaper, easier to perform and sample collection and 
preservation is easier (nail clippings form finger nails) and noninvasive. 
Pre analytical variation of the analyte as observed with other analytes is 
practically nil. 
Cost of testing is less compared to other indices. Precision of the assay is good.CV 
Calculated was 7.8% 
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INTRODUCTION 
DIABETES THE CLINICAL SCENARIO: 
Diabetes mellitus has become a worldwide epidemic and has to be 
identified and treated as early as possible to avoid micro- vascular and 
macro -vascular complications. Diabetes is a universal health problem 
which affects millions of people causing high morbidity and mortality. 
WORLD WIDE STATISTICS: 
As per WHO report, prevalence of diabetes is as shown below : 
YEAR PREVALANCE 
1985 
1995 
2010 
100 million 
135 million 
221 million 
 
TABLE – 1 :  DIABETES PREVALENCE 
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DIABETES IN SOUTH ASIAN COUNTRIES: 
Bangladesh, Bhutan, India, Pakistan, Maldives, Nepal and Sri 
Lanka contribute to nearly 25% of the diabetic population living 
throughout the world. (1) 
S. No Country Urban : Rural ratio 
1. INDIA 1.2 – 2.4 
2. Bangladesh 3.5 
3. Pakistan 1.4 
4. Sri Lanka 1.9 
5. Nepal 1.1 -5.8 
 
TABLE – 2 : DIABETES IN SOUTH ASIA 
 
Fig.1 : THE TREND OF URBAN TO RURAL PREVALENCE OF 
DIABETES 
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The life-style of rural population has been changing and the fast –
food craze has landed up in the rising trend of obesity and diabetes in 
India.  
 
 
 
 
 
 
Fig 2. PREVALANCE TRENDS IN SOUTH ASIAN COUNTRIES 
Following the western culture in Indian climatic conditions and 
technological advances that deprive us of our physical exercise make us 
succumb to the giant threatening the nations despite rich or poor. 
The cost of Diabetes management places burden on the shoulders 
of the country’s economy. (2) 
The national health bodies and their projects are lagging behind in 
coping up with the disease progress.  
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The identified risk factors in our population according to 
Jayawardane et al. in 2012 (3) are shown in the following table: 
 
TABLE - 3 : RISK FACTORS FOR DIABETES IDENTIFIED IN 
SOUTH ASIAN COUNTRIES 
There appears to be an increased incidence of DM at a younger age 
in our population and the risk is increased with even lower BMI. 
We require cost effective treatments and investigations to reach out 
to the rural population showing an increase in prevalence. The need to 
educate people about early symptoms and routine health checks are also 
vital to curtail the disease from engulfing the whole nation. 
In this study an attempt is made to establish a newer cost effective, 
simple, precise and noninvasive method of testing for long term glycemic 
control by estimating the glycated nail protein (ie.) fructosamine present 
in the keratin of finger nails.(4) 
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The cost of testing for blood glucose is three times higher and 
HbA1C is 15 to 40 times higher than the cost for nail fructosamine 
testing. 
The aim of the study is to establish whether finger nail 
fructosamine could be used to determine the long term glycemic status of 
an individual over the previous three months. Three months makes sense 
that the duration for growth of finger nail from nail matrix to the free 
distal margin takes on an average of three months. 
The objectives are to ensure the validity of this test by comparing 
the individual’s glycemic status using the existing standard glycemic 
index, HbA1C  and  also with serum fructosamine. 
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REVIEW OF LITERATURE 
 
DIABETES MELLITUS 
HISTORY OF DIABETES MELLITUS 
The earliest description of diabetes is evidenced in Ebers Papyrus 
the literature from 1550 BC. by Imhotep (5) a high priest, man of 
medicine who described polyuria. 
Arateus of capppadocia (150 AD) in his book acute and chronic 
diseases coined the term ―diabetes‖  meaning ―siphon‖ which implies the 
―liquefaction‖ of flesh and bones into urine (6). 
Susruta in 400BC described the syndrome of  Diabetes having a 
honeyed urine(7). 
Fredrick Banting, John McLeod Charles Best and JR. Collip, 
during 1921were the discoverers of insulin and showed that pancreatic 
extract from dogs lowered blood glucose levels .(8) 
1922 - ( Leonard Thompson 14 years of age at Toronto general 
hospital in Canada)  received purified pancreatic extract for correction of  
hyperglycemia and metabolic acidosis .( FIRST HUMAN INSULIN ) 
1925 – 66 - Newer synthetic insulins were developed. (9) 
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1955 – Sanger and collegues – succeeded in amino acid sequencing 
of insulin and  defined its structure. (10) 
1982 – recombinant human insulins .(11) 
CLASSIFICATION OF DIABETES MELLITUS : A CENTURY 
SINCE 1880 
1. Type 1 IDDM (Insulin dependent diabetes mellitus) 
2. Type 2 NIDDM ( Non- insulin dependent diabetes mellitus) 
3. Gestational diabetes mellitus 
4. Impaired Glucose tolerance  
5. Impaired fasting glucose 
 
Secondary diabetes – associated with pancreatic diseases,removal 
endocrinopathy and genetic syndromes.(12) 
Classification: WHO 1985: (13) 
1) IDDM 
2) NIDDM 
3) Malnutrition related diabetes mellitus 
a) fibro- calculous pancreatic diabetes 
b) Protein deficient pancreatic diabetes 
4) Gestational diabetes mellitus 
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5) Other types associated with diseases like glucaganoma, 
 thyrotoxicosis, drug induced eg. Diazoxide, phenytoin, furosemide, 
 insulinopathies etc. 
 
WHO CRITERIA for Glucose tolerance test interpretation using 75 
g glucose load: 
Type 
2-h OGTT result,             mmol/L (mg/dL) 
0 h 2 h 
Impaired fasting glucose
b
 
>6.1 (110) to <7.0 
(126) 
<7.8 (140) 
Impaired glucose tolerance
c
 <7.0 (126) >7.8 (140) to <11.1 (200) 
Diabetes
d
 >7.0 (126) >11.1 (200) 
 
TABLE : 4 - WHO CRITERIA TO DIAGNOSE DIABETES 
Any results obtained within the diagnostic limits should be 
repeated on another day before initiating any form of treatment. 
ADA Criteria:2010 (14) 
Fasting Plasma Glucose                               ≥ 126 mg/dL 
Casual                                                          ≥ 200mg/dL 
2 hours (post 75gGlucose load                    ≥ 200 mg/dL 
HbA1C                                ≥ 6.5% 
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In the criteria of  WHO expert committee 1997,HbA1C is not 
included. 
Casual – Any time of the day without relationship to previous food 
intake. 
Pathogenesis of NIDDM: 
Two defects are reported, (15) 
1. Insulin resistance  
2. Beta cell dysfunction of pancreatic tissue. 
Insulin resistance is defined as a decreased biological response to 
normal concentration of  circulating insulin. The primary cause is 
obesity and the quantity of body fat is proportional to insulin 
resistance. (16) TNF α and resistin by adipose tissue oppose the action of 
insulin. A decrease  in levels of adiponectin also contributes to insulin 
resistance. 
Beta cell dysfunction develops secondarily and there is a loss of 
glucose induced insulin release. This is termed as selective glucose 
unresponsiveness. 
 n inverse relationship exists with degree of physical activity and 
development of the disease. 
Genetic factors also contribute to the disease. 
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FIG.3 -  PATHOGENESIS OF NIDDM 
 
EPIDEMIOLOGY: 
            The reports of WHO suggests the prevalence of 100 million in 
1985,151 million in 2000, 221 million  in 2010. 
           The explosive increase of non- insulin dependent diabetes mellitus 
occurring due to a sedentary life style places a burden on the economic 
status of the country as it would cost more for diagnosis, management 
and supportive care for the micro vascular and macro vascular 
complications of the disease. 
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Historical aspects: 
Pre insulin era:  
 Mathew Dobson in 1776 – boiled urine of diabetics till dry and 
found its resemblance to brown sugar .(17)         
 John Rollo, in 1797 - reported the presence of increased sugar in 
the blood of diabetics. 
 Wollaston 1828 - attempted to measure blood sugar, but did not 
succeed.  
 Chevreuil in 1914 -reported the sugar in the blood resembled 
dextrose or glucose .(18) 
 Specific methods to measure blood glucose as reducing substance 
developed  later. 
TOOLS IN DIAGNOSING DIABETES: URINE GLUCOSE, 
BLOOD GLUCOSE 
 The Benedicts urine test used by S.R. Benedict was time 
consuming and caused bad odour. The next step was clini-test tablets 
which gave a crude measure of glucose control during 1950s. 
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 Self monitoring of Blood Glucose SMBG was introduced in 1970 
with glucose oxidants impregnated strips. They are a boon to diabetic 
patients and treating physician to achieve a good glycemic control. Other 
advancements are gluco-watch based on iontophoresis which measures 
glucose in subcutaneous fluid or a subcutaneous needle to monitor blood 
glucose continuously(19). 
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NAIL AND  KERATIN 
 History 
 Structure and functions 
 Types 
 Composition 
 Glycation 
Keratin belongs to the class of fibrous proteins. Fibrous proteins 
are classified into three classes. 
1. Keratins which form protective covering  of the skin, hair and 
nails, hooves, horns, scales beaks, quills feathers, fur and wool. 
Actin and myosin of muscle and fibrinogen which takes part in 
coagulation are other fibrous proteins. 
2. Silk and insect fibers. 
3. Collagen and hides which give structural support and strength. 
A fibrous protein has polypeptide chains arranged in long strands 
or sheets. The Cα-N bond axis (φ) and Cα-C axis(ψ) are unchanging and 
recur over long stretches of the chain    
 14 
Structure:  
Alpha keratins are made up of  alpha helices  as suggested by 
W.T.Astbury  in1930, wound around in a right handed coil like Aubusson 
tapestry .(thread-coiled coil) (20) 
 
Fig. 4 : BASIC UNIT OF KERATIN 
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THE ALPHA KERATIN:                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                              
FIG . 5 : ALPHA HELIX        FIG. 6  : THE BETA SHEET                               
Proto fibrils (20A°) are the basic units that form keratin. One 
protofibril is made up of three right handed alpha helices arranged in a 
left handed coil. Nine protofibrils are bundled together surrounding two 
more of axially arranged protofibrils to form a micro fibril (80A°) .This 
forms a eleven stranded cable like structure. The super twist is left 
handed and the places where the three helices contact contain 
hydrophobic aminoacids. R groups of aminoacids in the helices are found 
in interlocking pattern. Hundreds of microfibrils which are embedded in 
sulphur -rich protein matrix are cemented to form irregular bundles called 
macro fibrils. (21) 
The helices are crosslinked with disulfide bonds of cysteine 
residues.The hydrogen bonds also strengthen the helices but are weak. 
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The keratins are classified as soft (skin) and hard keratins (horn, nail, 
hooves) by their sulfur content. 
Beta keratin:  
Classical examples are wool and feathers where polypeptide chains 
are arranged in axis parallel to the fiber axis. Neighbouring chains are 
linked by hydrogen bonds and run in opposite directions and forms sheet 
like structure. (22) 
Composition of the nail: 
The keratins of nail belong to either low sulfur content group of 
molecular weight 40 – 60 kDa which constitutes 20% or high sulfur 
group of keratins (10 – 25 kDa)  about 80%  and a high glycine- tyrosine 
matrix proteins( 6-9 k Da) (23). The fibrils are seen embedded in the 
matrix. Regional differences of keratin expression within the nail  is also 
noted. The main lipid of the nail is cholesterol. Fat content is 0.1 – 1% 
and water content is 7 – 12%, calcium is 1% of weight, sodium, 
magnesium and phosphorus are increased in cirrhotics. Iron and copper 
are increased in children. Alcohol can permeate and hydrophobic 
molecules and steroids can permeate into the distal nail plate.(24) 
Over 30 types of high sulfur proteins are identified in the human 
nail. 
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TYPES OF KERATIN AND ITS DISTRIBUTION: 
More than twenty types are known.(25) 
Alpha                            Beta                                      Occurrence 
 
Keratin1,2   9,10          Cornea , keratinocytes 
 
    3                                   12                           Cornea 
 
    4                                   13                 stratified epithelium 
 
   5                                   14,15              stratified epithelium 
 
   6                                   16,17              Squamous epithelium 
 
   7                                   19                            ductal epithelium 
 
   8                                   18, 20                      simple epithelium 
 
TABLE - 5 :  TYPES OF KERATIN 
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Keratins expressed in the nail:   
TABLE : 6 - KERATIN EXPRESSION IN NAIL 
S.No Type Structure expressed 
1 K5/K14 Nail bed , germinative matrix 
2 K6/K16 Nailbed 
3 K1/K10 Proximal nail fold germinative matrix 
          
Trichocyte keratins expressed in the nail are HaKa1-4,Ha Kb1-4 
and HaX and HbX.(26) 
GLYCATION: 
Glucose binds to epidermal proteins non-enzymatically as seen in 
serum proteins and hemoglobin but at a slower and constant rate 
proportional to the glucose concentration in the extracellular fluid.  
 ―Glucose binding to keratin and proteins of the insoluble stratum 
corneum fraction appeared to occur at practically the same rate, and it is a 
first-order reaction with regard to the glucose concentration. Water-
soluble proteins of the stratum corneum undergo non-enzymatic glycation 
preferentially (on average, 83.4% of the total amount of glycated proteins 
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is present in the soluble fraction), regardless of the initial content of 
glycated proteins in the sample.‖(Marova et al 1995)(27) 
THE HUMAN NAIL: 
Nail structure:  
Nail anatomy is the same in fingernails & toenails 
FIG -  7  : STRUCTURE OF HUMAN FINGER NAIL 
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It comprises of 
                         Nail matrix 
                         nail plate and                                  
                         cuticular system 
                         Nail bed  
                         Nailfolds  
                         Lunula 
The nail plate is made up of hard keratin and is of horny and 
transluscent nature. 
It varies in thickness between 0.5 and 0.75 mm. 
Histology: 
             Three layers are identified 
             Thin dorsal lamina 
              Thick intermediate layer 
              Ventral  layer. 
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            The ventral layer is about one-fifth of the nail thickness and is 
derived from the nail bed and the rest from the nail matrix. 
Microscopic appearance: 
The nail plate shows closely packed flattened squamous cells in 
close opposition because of tortuous and interlocking plasma membranes 
(28).The soft tissue where the nail overlies is called the nailbed. 
It consists of  
1. A vascular matrix contiguous with the periosteum of the 
distal phalanx. 
2. Two or three celled layer of epidermis (living layer of cell) 
above which dead cells of the ventral nail plate lies. As the 
cells differentiate, they are incorporated into the ventral 
surface of the  nail plate and move distally with this layer. 
Physiologic factors affecting nail growth rate: 
Finger nails grow at a rate of 0.1mm per day and toe nails at one 
third of this rate. (29) 
1. Young age, pregnancy ,male gender   -  increased growth rate 
2 . Lactation, old age, female gender      -  decreased growth rate 
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THE HEMOGLOBIN AND ITS GLYCATION 
Structure and function: 
Hemoglobin is exclusively found in the red blood cells and 
transports oxygen  to the tissues 
Composition: 
Hemoglobin consists of two alpha chains and two beta chains 
encasing a heme moiety within the core of each chain. 
Types: 
Normal hemoglobins: 
TABLE – 7 :  NORMAL HEMOGLOBIN 
Name Composition % distribution 
Adult A1 Ααßß Major form97% 
AdultA2 Ααðð Minor form < 3% 
Foetal form-HbF ααɤɤ Major form in foetal life 
 
Mutant forms: 
                   They are significant to a clinical chemist because they 
interfere in the HbA1C assay.         
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Various minor components have been identified. 
Commonly encountered ones are the following: 
Name Normal aminoacid–position-charge Replaced by          
charge 
HbS 
(Sickle) 
Glutamic acid     –   ß 6 -negative Valine                 
positive 
HbC Glutamic acid    – ß 6    -negative Lysine                  
positive 
HbE Glutamic acid  – ß 26    -negative      Lysine                 
positive 
 
TABLE  - 8 : HEMOGLOBIN VARIANTS 
 
Fig. 8     STRUCTURE OF HEMOGLOBIN 
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The structure of heme is designed in such a way that the methene 
bonds resonate and it has a characteristic absorption spectrum. 
All hemoglobin derivatives have characteristic absorption spectra. 
The variant hemoglobins do not differ except for methemoglobin 
which also differs from the spectrum of HbM.(30) 
This property is made use of in estimating the total hemoglobin in 
immuno-inhibition  assay for HbA1C estimation  in this study. 
GLYCATION IN HEMOGLOBIN: 
The non- enzymatic addition of a sugar residue to the amino group 
of proteins is called glycation. 
 The IUPAC terminology used is neo-glycoprotein. The term 
glycation is preferred and widely used. (31) 
The normal hemoglobin consists of HbA1 - 97%, HbA2- 2.5%and 
HBF<0.5%. 
Chromatographic separation of HbA identifies several minor 
hemoglobins. 
HbA1a1-  fructose 1,6 di phosphate to N terminal  valine of the   ß 
chain. 
 25 
HbA1a2  -  glucose 6 phosphate attached  to  N terminal  valine of 
the   ß Chain 
HbA1b    - pyruvic acid attached to N terminal valine of the ß chain 
HbA1C   - glucose attached to N terminal valine. 
The rate of glycation is directly proportional to the glucose 
concentration in the blood and is unaffected by daily fluctuations. 
Hence it is considered as a tool for determining the long term 
glycemic control.     
HEMOGLOBIN A1C - STRUCTURE 
  
 Fig -  9:  A.  Blood  vessel    B. Glycated hemoglobin    
   C.  HbA1C versus  Blood Glucose 
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History of HbA1C 
1958 – Huilman and Mayering separated HbA1c using 
chromatographic columns. 
Samuel Rahbar etal – found an increase in proportion of HbA1c is 
seen in diabetes(32) 
1975 – Bunn and co-workers described the reactions occurring at 
the molecular level 
1976 – Antony Cerami Ronald, Koenig and coworkers proposed it 
for monitoring the degree of control of  glycemia. 
Methods for detecting HbA1C: 
1. High Pressure Liquid chromatography (HPLC) 
2. Immuno assays 
3. Enzymatic methods 
4. Capillary electrophoresis. 
5. Boronate affinity chromatography 
6. Colorimetric techniques. 
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Point of care devices use the boronate affinity or immuno - assays 
for testing HbA1C. 
THE GLYCEMIC INDICES: (33) 
Short term control :   
1. Plasma glucose   (hours) 
2. Fructosamine serum (1 -3 weeks) 
3. Glycated albumin serum ((1-2weeks) 
4. 1,5- anhydro glucitol serum (1 -14 days) 
5. Long term control:(6 – 12 weeks) 
HbA1C and A1C Derived Average Glucose (calculated parameter) 
REACTION OF GLUCOSE WITH HEMOGLOBIN A1C: 
The glucose transporters in the RBC membrane allows glucose 
entry into the cell. 
And they when present in excess bind to N terminal valine and 
epsilon amino group of the protein portion of the hemoglobin. 
The  binding is initially reversible  (PRE HbA1C- the unstable 
aldimine form) (34 )and glucose  can re- enter into the cytosol if high 
blood glucose levels are not persistent. 
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But whenever the duration of this temporary association is 
prolonged, there occurs a permanent modification of the binding called 
AMADORI rearrangement. (35) 
 
FIG.10 -   GLYCATION AT THE MOLECULAR LEVEL. 
The more the excess in blood glucose, the more is the glycation . 
The glycated product thus formed is called GLYCATED 
HEMOGLOBIN - HbA1C. 
This is the reason why the percentage of glycated hemoglobin is 
more in a patient with diabetes. The glycation degradation products 
damage the membranes and cause organ damage.  
SIGNIFICANCE OF HbA1C: 
The significance of HbA1C is that it gives an average estimate of 
blood glucose in the individual and it tells retrospectively the same, for a 
period of 6-12 weeks ie the average life span of RBC. 
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This is the concept behind the determination of HbA1C as an 
indicator of long term glycemic control in diabetic patients. 
Glycation occurs in normal population and <5% of hemoglobin is 
expected to undergo glycation in euglycemia. 
HbA1C as the glycemic index: 
Advantages: 
1. A random, non-fasting venous blood sample with anticoagulant  can 
be used for the assay. 
2. Minimal sample volume obtained directly from a finger prick is 
adequate in point of care (POC) testing devices. 
3. Results are also faster in POC devices (8 minutes) and routine 
 procedures followed for testing.( 15 – 30 minutes ). 
4. The assay has been standardized by NGSP  . (36) 
Disadvantages: 
1. Results are not reliable in individuals with hemoglobin variants as 
they interfere in the routinely used HPLC methods. 
2. Anemias where red cell life span is affected. 
3. Needs sophisticated and costly equipments and hence the high cost 
of testing. 
 30 
GLYCATION OF PROTEINS: 
Apart from glycation of hemoglobin, the proteins where glycation 
is known to occur is collagen , tubulin, ocular lens protein, peripheral 
nerve protein, tendon protein, arterial proteins, elastin in lung anti-
thrombin III, erythrocyte membrane proteins ,fibrinogen, lipoproteins, 
ribonuclease A, platelet protein, urinary amino acids and peptides.(37) 
The glycation process is typically non enzymatic and it differs from 
the enzymatic process which occurs post- translationally during protein 
synthesis. 
The same product occurs in all proteins of plasma, cell membrane 
and extracellular matrix and is collectively termed as fructosamine in 
general and glycated albumin when it is spoken of in albumin.(38) 
Fructosamine assays available are 
1. Chemical methods:  
They measure nonspecifically all glycated lysine residues. 
A) Nirto blue tetrazolium method 
B) Thio barbituric acid method 
C) Phenyl hydrazine method 
D)  Furosine method 
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2.    Chromatography: 
Boronate affinity chromatography 
 3. Immuno Assays: 
Immuno turbidimetry using specific antibodies to glycated 
albumin  
4. Enzymatic method: 
Using endo-peptidases and lysyl oxidase by photometric 
techniques.(39) 
Advantages: 
Serum fructosamine is a cheaper method  and shows short term 
control of glycemia over weeks. 
The assay can be performed in cases of hemoglobin variants when 
HbA1C is not reliable. 
It can be of use in gestational diabetes. 
Disadvantages: 
The assay standardization and confounding factors limit its 
usefulness.(40) 
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METHODOLOGY 
INTRODUCTION:  
Recent studies(41) showed  that fructosamine in nail estimation can 
be used as a measure of long term control of blood sugar in diabetic 
patients. In finger nails it gives an estimation of blood glucose levels over 
the previous three months. Nail clippings are taken for testing. 
For Hb A1C the standard methods in use are HPLC method , 
immuno-turbidimetry and enzymatic methods, all of which are expensive 
whereas nail fructosamine by Nitroblue tetrazolium method is cost 
effective. 
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AIM 
TO TEST FOR LONG TERM GLYCEMIC CONTROL 
USING A NEWER PARAMETER- GLYCATED NAIL PROTEIN 
(FRUCTOSAMINE) IN FINGER NAILS. 
OBJECTIVES: 
- To prove that fructosamine levels in nail protein (finger nails) by 
Nitro Blue Tetrazolium method can be a useful indicator of long 
term glycemic  control (over the past 3 to 5 months) in diabetic 
patients      
- To analyze  the efficacy of the method by comparing it with 
glycated hemoglobin (HbA1C)  by immuno - turbidimetric method  
- To compare with serum fructosamine levels by NBT method 
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STUDY DESIGN: 
Place of study  : Stanley Medical College and Hospital,Chennai. 
Duration of study : 6 months April 2014-September2014 
Type of Study  : Longitudinal study. 
Sample size and mode  of sampling:  Simple random sampling  
Cases: 30 diabetic patients 
Controls:30 healthy non-diabetic individuals. 
 Inclusion Criteria: 
Type II  Diabetic patients (ADA Criteria FBS > 126 mg% ) . 
The patients included are on 
Oral hypoglycemic agents alone or  
On Insulin and Oral hypoglycemic agents  
Exclusion Criteria:  
            Diabetic patients with 
Nephropathy 
Retinopathy 
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Persistent  hyperproteinemia due to any cause 
                     Those with diseased fingernails  
                     Artificial coloring on nails eg.  Mehenti or nail polish 
Materials required: 
1. Hb A1 C kit for immunoturbidimetric method   
2. For nail Fructosamine and serum fructosamine assay: 
         a. Nitro Blue Tetrazolium reagent – colorimetric method 
         b.  Fructosamine calibrator 
Specimen  collection and processing: 
1. Nail clippings about 10 mg.(Two samples – initial and final) 
2. Venous blood with anticoagulant 3 ml. (HbA1C)        
collected in potassium EDTA containing  vacutainer. 
         (Two samples  - initial and final) 
3. Three ml of whole blood for separation of serum. 
(fructosamine) 
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Once in three weeks. 
Sample is collected in clot activator containing disposable tubes 
and allowed to stand for one to two hours as required and serum collected 
and stored in -20° in a   deep freezer.  
Methods:  
1. Nail fructosamine assay: Endpoint - Bakan et al.(42) 
* Nail clippings of 10 mgs  are weighed after standardizing the 
balance  
* Cut into pieces of   about 2 – 3 mm  
* 1 ml of NBT reagent added                   
* Incubated at 37°C for 1 hour  
* Readings taken at 530 nm. 
* The values are compared with absorbance of fructosamine standard 
and results are calculated. 
2. Serum fructosamine assay:Kinetic (43) 
* To the serum NBT reagent is added and rate is assayed. 
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* The rate of formation of formazan compound is proportional to the 
amount of  fructosamine present in the serum. 
 
* Because of good precision this assay is preferred. 
3. HbA1C: ( Immuno turbidimetric assay) 
* This is an NGSP certified method and interferences by variant *
 hemoglobins   are less. Hence this method is chosen for assay of 
 HbA1C. 
 
* Both initial and final HbA1C were done for every patient at the 
beginning and end of the study respectively, and at the same time 
nail clippings are taken. 
 
* Interval allowed between the two samples varied between 8 – 12 
weeks as feasible with patient compliance.   
 
Ethical considerations   
 
The integrity, safety and identity of participants in this study were 
preserved as per the recommended guide lines by the Institute’s Ethical 
Committee.  
 
The study was approved by the Institute’s Ethical Committee, The 
Government Stanley Medical College and Hospital, Chennai -600001.  
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Consent: 
          A written, informed consent was obtained from the patients who 
were willing for follow up regularly and to participate in this study. 
PATIENT SELECTION AND PARAMETERS :  
Selection of patients for the study was done from the patients 
attending Diabetology Outpatient Department of Government Stanley 
Medical College and Hospital after getting approval from the Institute’s 
Ethical Committee. NIDDM was chosen for the study because acute 
variations in the blood glucose level is less  rather than in IDDM. The 
study was observational and the selected patients were followed up 
longitudinally for three months for determination of their glycemic status 
either weekly or biweekly follow-ups .The  indices determined to assess 
the glycemic status in this study are 
1. Fasting blood glucose –mean  
2. Serum Fructosamine Mean 
3. HbA1C  initial and final and average estimated glucose  
  (derived value from  HbA1C - (MBG) 
The three indices are correlated with nail fructosamine of the same 
individual to evaluate this promising cost effective glycemic index and its 
usefulness in longterm glycemic control.  
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Control group: 
Healthy age and sex matched individuals with or without a positive 
family history were selected for the study. The same  parameters  were 
performed  for all controls after obtaining informed and written consent. 
Assessment of Nail growth rate: 
Also the individual nail growth rate was assessed for one month for 
the population studied to verify the nail turn over time.The nail turnover 
time was found to be 0.1mm per day on an average.The measured values 
varied between 3-5mm in a month among the one hundred and four 
individuals evaluated. 
Patient ID and documentation: 
The patients selected were issued Identification number as and 
when they were registered for the study. 
They were evaluated based on the proforma and clinically assessed 
whether they were fitting into the criteria for this study. 
The observations were recorded and the data analysed using spss 
version16. 
A physical status examination was also conducted. 
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Confirmation of Diabetes mellitus : 
Fasting Blood Glucose (FBG)>126mg%  (44) 
 Testing for exclusion criteria: 
           1. Urinary Protein Creatinine Ratio 
           2. Serum Protein and Albumin. 
Urine Protein creatinine ratio: 
Specimen collection and processing: 
Morning void fresh urine was collected in clean plastic containers 
and examined within one hour of collection. 
The urine collected was kept in the refrigerator if any delay is 
expected in testing of the sample. 
Samples were centrifuged if found turbid . 
Method: 
Sulphosalicylic acid method  Kingsbury’s method:(45) 
Instrument used : 
Semi-automated analyser (Merck Microlab 300) 
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Principle: 
The proteins present in the urine reacts with sulpho-salicylic acid to 
form turbidity  
Reference Interval: <80mg/day at rest. 
                                 Upto 150 mg/ day after strenuous exercise. 
Estimation of Urinary Creatinine: 
Method: 
JAFFE’S KINETIC METHOD(46) 
Reference interval: 
      1-1.5 mg/day 
Urine Protein Creatinine Ratio: (47) 
          Reference interval : 
                                  0.02 – 0.2 
                                   > 0.2 gross proteinuria( after confirmatory test) 
Estimation of serum proteins:(48) 
Specimen preparation: 
Serum separated from whole blood centrifuged at 2000 rpm for  10 
minutes and tested on the day of collection 
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METHOD: 
BIURET METHOD  -Endpoint. 
Aim: 
To estimate total proteins in the serum 
Principle: 
Proteins in the serum reacts with Biuret reagent to form a purple 
coloured complex which is measured photometrically .  
 Referrence interval: 
Adult 6.4 -8.3 gms/dL 
All individuals included in this study had their protein values 
within the reference range. 
Estimation of serum Albumin:(49) 
METHOD: 
BROMO CRESOL GREEN METHOD ( ENDPOINT) 
Aim: 
          To determine the amount of albumin present in the serum 
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Principle: 
At pH 3.68. albumin acts as a cation and binds to the anionic dye,  
Bromo Cresol Green  (BCG) forming a green coloured complex which 
can be read photometrically. 
Referrence interval: 
                Adults      -   3.2 – 5.2gms/dL 
HEMOGLOBIN A1C ESTIMATION : (50) 
METHOD: TURBIDIMETRIC IMMUNO INHIBITION ASSAY 
Instrument: Cobas C 311 Analyser. 
 
FIG. 11 : COBAS C 311 ANALYZER 
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Aim:             
To determine the HbA1C in anticoagulant added whole blood. 
Principle:  
The hemolysed sample containing HbA1C reacts with antibody to 
N terminal portion of the beta chain of hemoglobin to form soluble 
antigen antibody complexes.  
A poly hapten added reacts with excess of antibody forming  
insoluble Ag - Ab compexes which can be measured 
photometrically.(Turbidimetry) 
Specimen collection and processing: 
Whole blood from vein or capillary collected in Na or K EDTA 
vacutainers. 
Samples are analysed on the same day of collection and preserved 
in  2 - 8 ° C until the time of analysis. 
Preparing hemolysate:  
The hemolysing reagent and Sample were taken in the ratio of  1 : 
100, mixed in shaker or vortex mixer at room temperature for 1-2 
minutes.  
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Hemolysate was stable for 6 months at -20°C. 
Reagent composition: 
R1- Antibody reagent: 
MES buffer   0.025mol/L 
TRIS Buffer  0.015 mol/L, pH 6.2 
HbA1C Ab ( bovine serum )≥ 0.5 mg/mL 
Stabilizers 
Preservatives 
R2  - Polyhapten reagent 
MES Buffer 0.025 mol/L 
TRIS Buffer0.015mol/L pH 6.2 
HbA1C polyhapten ≥8µg/mL 
Stabilizers and Preservatives 
R3 Hemolyzing reagent: 
Contains TTAB as detergent 
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Assay parameters: HbA1C- W2 
            Assay type : 2‑Point End 
Reaction time  : 10 minutes 
Assay points  :  23‑57 
Wavelength (sub/main): 660/340 nm 
Reaction direction  : Increase 
Unit                         : g/dL 
                 Reagent pipetting     Diluent (H2O) 
                 R1 120 μL                  –           
R2 24 μL                    – 
ASSAY PARAMETERS Hb-W2 
              Assay type 2‑Point End  
              Reaction time – 10 minutes 
              Assay points      -  23 
              Wavelength -(sub/main) 660/376 nm 
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              Reaction direction- Increase 
              Unit g/dL 
Reagent pipetting     Diluent (H2O) 
              R1 120 μL                       – 
              R2 24 μL                         – 
Calculation: 
Estimated average glucose: 
[mmol/L] = 0.146 × HbA1c (mmol/mol) + 0.834 or 
Estimated average glucose: 
[mg/dL] = 28.7 × HbA1c (%) - 46.7 
HbA1c (%) = (HbA1c/Hb) × 91.5 + 2.15 
(mmol/mol HbA1c acc. to IFCC)(17) 
HbA1c (mmol/mol) = (HbA1c/Hb)x 1000 
Reference Interval: 
HbA1C :       4.3‑18.9 %  
Hemoglobin: 4‑35 g/dL 
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STANDARDISATION: 
6 Point calibration was done with calibrator for HbA1C 
The standard graph is used for calculating the sample values. 
Quality control: 
Quality control is performed using the control provided with the kit 
for high and low values. 
Estimation of Plasma glucose: (Fasting) 
INSTRUMENT: 
Merck Microlab 300 
Method:  Trinder’s method (51) 
Principle: 
1. Glucose present in the sample is oxidized by glucose oxidase to 
gluconic acid and hydrogen peroxide. 
2. Hydrogen peroxide reacts with phenolic compound in the presence 
of amino- anti pyrine to form a coloured complex . 
Reference interval: 
       Adult:  < 100mg/dL 
       Pregnancy -  <95mg/dL 
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ESTIMATION OF SERUM FRUCTOSAMINE: 
INSTRUMENT: 
FULLY AUTOMATED ANALYZER 
 
Fig.12 : AU 480  BECKMAN COULTER 
METHOD: 
Modified nitroblue tetrazolium method (by Baker et al) (52) 
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Aim:  
To determine the concentration of fructosamine present in the 
serum of the given sample. 
Principle: 
Fructosamine reduces Nitroblue tetrazolium in alkaline conditions 
to form a coloured formazan compound which is measured 
photometrically at 530 nm. The  intensity of the colour developed is 
proportional to the concentration of fructosamine in the serum. 
Specimen collection and processing: 
Serum separated from clotted whole blood was analysed. 
Samples were stable at -20°C for 2months. 
Once thawed, the sample was not  refreezed. 
Reagent composition: 
Nitroblue tetrazolium    --       0.48 mM             
Triton X 100                 --       2.2 gm% 
Sodium carbonate         -         100 mM  pH 10.3 
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Reagent preparation: 
1. Buffer stock: 
           a) Sodium Carbonate 1M (100ml) 
106  gms of dried sodium carbonate is weighed  and 
transferred into a clean glass beaker   
                     80 ml of deionized water is added and mixed well. 
The contents are transferred into a clean dry 100ml 
volumetric flask and made upto 100ml. 
                     Stored in refrigerator at 2-8°C. 
b) Sodium hydrogen carbonate 1 M:(100ml ) 
84 gms of  dried sodium hydrogen carbonate is  weighed and  
made upto 100 ml in a volumetric flask , mixed well. 
                     Transferred and stored at 2-8°C. 
Working buffer: 
1 in 10 dilution of buffer stock was prepared from 1M solutions of 
Sodium carbonate and sodium bicarbonate to obtain 0.1M solutions. 
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Standardization of pH Meter: 
After washing the probe with deionized water, it was placed in 
deionized water for 30 minutes. 
Standard solutions of pH 7.0 and 10.0 were used to standardize the 
pH Meter. Reagent preparation: (100 ml)     
25 ml of sodium carbonate 0.1 M solution was taken in a clean 
glass beaker and  65 ml of sodium hydrogen carbonate 0.1 M solution 
was added.     
The pH is measured and adjusted to 10.3 by titrating with sodium 
hydrogen carbonate 0.1M and made upto 95 ml in a volumetric flask. 
The NBT powder was weighed (41 mgs),taken in a  beaker, 
dissolved with 2-3 ml of deionized water and 2.2 gms of the detergent. It 
was mixed well and transferred into the volumetric flask containing   
buffer. 
The final volume of 100 ml was made and final pH verified. 
The reagent was ready to use. 
Storage and precautions: 
The reagent was stored in a dark brown bottle . 
                   Temperature : 2-8°C 
                    Stable for 5 – 7 days. 
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Direct bright light should be avoided as it deteriorates the NBT 
activity. 
Procedure: 
Both reagent and serum to be analyzed should be brought to room 
temperature. 
Prewarming of the reagent volume to be used is done while using 
spectrophotometer or semi- auto analyzer. 
Dilution ( 1:5 ) is made for analyzing in spectrophotometer and 
calculation is done accordingly. 
Assay parameters: 
Mode   : Kinetic 
Wavelength    : 530nm 
Reagent volume   : 500µL 
         Sample volume    : 25µL 
        Reaction direction  : increasing 
        Blank                      : reagent blank 
       Linearity               :  upto 800mM 
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Calculation: 
                                                         ∆ Absorbance of the test 
Fructosamine in serum in µmol/L = _____________   X conc.of the std. 
                                                       ∆ Absorbance of the std. 
Standardisation of the procedure: 
            The procedure is standardized using commercial fructosamine 
standard .  
FIG – 13 : SERUM FRUCTOSAMINE KINETICS: 
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Quality control: 
Standards of known concentration prepared from the calibrator is 
used for verifying the test results. 
 55 
ESTIMATION OF NAIL FRUCTOSAMINE: 
METHOD: 
NITROBLUE TETRAZOLIUM METHOD (BAKER et al.)(44) 
INSTRUMENT: 
UV  1800 SPECTRPHOTOMETER(Schimadtzu) 
 
Fig.14  : SPECTROPHOTOMETER 
Aim: 
To determine the fructosamine levels in the human finger nail 
clippings. 
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Principle: 
The fructosamine formed in the nail protein keratin and the ventral 
nail plate throughout its growth period across the nail bed was determined 
from the nail clippings taken from the free edge of the finger nail by its 
ability to reduce the nitroblue tetrazolium to a coloured formazan 
compound .This was measured photometrically at 530 nm. The  intensity 
of the colour formed was directly proportional to the fructosamine present 
in the given nail sample. The assay was based on the property of the nail 
being susceptible to less hydrophilic substances to diffuse through  the 
nail and the diffusion rate being uniform due to thickness of the nail plate 
being uniform with minimal inter individual variations. 
Specimen collection and processing:  
 
FIG.15 :  NAIL – SPECIMEN  PROCESSING 
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The selected patient population was instructed to clean the nails by 
washing with soap and water as usual at their homes. 
Nail clippings were taken using a nail clipper . 
For uniformity , the nails from four fingers except thumb are taken 
for the assay. 
The finger nails known to be coated with substances eg. Nail 
polish, mehenti were avoided. 
The patients included in the study were asked to avoid such 
decorative works and biting the nails  during their follow-up period of 10 
– 12 weeks. 
The nail clippings and venous blood for HbA1c were taken 
simultaneously. 
Processing and storage: 
The clippings were preserved in 0.1 ml microfuge tubes. 
It can also be collected in plain white paper (without print ink or 
anycolour) and preserved in clean plastic boxes. 
They can be preserved at room temperature for about three months. 
Moisture and contaminants were avoided during storage. 
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Before testing the nails were cut into tiny bits of 2-3 mm 
approximately. 
The nail bits were weighed in a balance which was standardized 
using 100mg and 5mg standard weights. 
The weighed nail substance was transferred into clean glass test 
tubes  after labelling. 
One ml of prewarmed NBT reagent (room temperature) was added 
to   each of the test tubes. 
They were arranged in a rack and incubated at 37°C for one                   
hour.(Timer set)                  
After 30 minutes of  incubation, the test tubes were shaken and 
mixed. 
The  tubes were removed ensuring completion of one hour 
incubation for all the samples. 
Readings were taken in a spectrophotometer with reagent in the      
reference cell. 
Preparing the spectrophotometer: 
While after completion of 45 minutes of the reaction time, the 
spectrophotometer was switched on and self check time allowed. 
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Spectrometer was programmed as for photometric settings. 
Assay parameters: 
Mode    : End point 
Wavelength    : 530 nm 
Reaction time     : 1 hr 
Reaction temperature  : 37°C 
Reagent volume      : 1 ml 
Sample by weight    : 10 mg 
Unit                : µmol/L/mg 
Cuvette volume       : 1.5 ml 
FIG.16 : THE END POINT IN NAIL FRUCTOSAMINE ASSAY 
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Calibration: 
Fructosamine standard in human albumin preparation is used to 
standardize the assay. 
The concentration  is 404µmol/L 
Preparation of standards: 
The standard used should be within or close to the reference 
interval.(53) 
Hence from the calibrator 8µmol standard is prepared and used as 
standard. 
The concentration  is 404µmol/L 
Preparation of standards: 
The standard used should be within or close to the reference 
interval. 
Hence from the calibrator 8µmol standard was prepared and used 
as standard. 
The standard solution was weighed and 10mg eqiuvalent  was 
taken for the assay for standardization. 
Dilutions were prepared using normal saline. 
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The standard solutions were brought to room temperature prior to 
use. 
The required volumes were prepared freshly prior to use to avoid 
repeated freezing and thawing. 
 STD GRAPH:    
FIG.17 - STANDARD GRAPH NAIL FRUCTOSAMINE ASSAY 
 
Calculation: 
The quantity of fructosamine in nail is calculated using the 
following formula  
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Fructosamine present                   Absorbance of test    
in the nail /gm of the substance = _____________x conc. of the standard 
                                                     Absorbance of the standard     
 
Concentration of standard = 8µmol/L 
Unit conversion: 
The result obtained per 1000µL for 10mg is in µmol/ Kg 
equivalents. 
The conversion is done for g equivalents by multiplying it by1000. 
Referrence interval:l(54) 
Male:    0.58 – 3.8µmol/gm equivalent of nail 
Female:  0.55 – 3.32µmol/gm equivalent of nail 
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RESULTS AND STATISTICAL ANALYSIS 
The present study is a 6 months longitudinal study of diabetic 
patients in Stanley Medical College and Hospital, Chennai from the 
month of April 2014-September2014.The long term glycemic control of 
diabetic patients were analyzed using a newer parameter-glycated nail 
protein (fructosamine) in finger nails and the results were  compared with 
the controls. 
ANALYSIS OF CASES     
All known diabetic patients who were taken in to the study were 
analyzed completely beginning with history taking which involved 
age,sex, duration of the illness, family history of diabetes. General 
examinations like pulse rate, blood pressure, height, weight were taken. 
Patient’s risk factors were analyzed in terms of lipid profile and BMI and 
associated co morbidities were also analyzed..    
Fasting plasma glucose, HbA1C levels, serum fructosamine levels 
and nail fructosamine levels were taken for analysis to assess their 
glycemic status during the period of study. Plasma glucose and serum 
fructosamine were taken as mean values. HbA1C and Nail fructosamine 
were performed twice (initial and final) for individual 
comparison.(55).Both these parameters were also compared and 
analyzed. 
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TABLE :  9  - DISTRIBUTION OF AGE GROUP 
AGE GROUP NUMBER OF PATIENTS 
0-10 0 
11-20 0 
21-30 1 
31-40 5 
41-50 12 
51-60 8 
61-70 9 
71—80 0 
81-90 0 
91-100 0 
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       In the present study 35  diabetic patients were studied . Most of the 
patients belonged to the age group of 41-50. The mean age of the study 
group was 51.1years. 
 
 
 
 
 
 
 
FIG.18  - AGE DISTRIBUTION 
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TABLE - 10 : SEX DISTRIBUTION 
PATIENT’S SEX NUMBER 
MALE 8 
FEMALE 27 
              
 
 
 
   
 
 
 
FIG.19 -  SEX RATIO - CASES 
In the above study females constituted 77% of the study population 
among patients. 
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TABLE – 11 : DURATION OF THE DISEASE 
DURATION 
NUMBER OF 
PATIENTS 
PERCENTAG
E 
<1 YEAR 10 28.6 
1-3 YEARS 8 22.9 
3-5 YEARS 7 20 
>5 YEARS 10 28.5 
 
                             FIG.20 : DURATION OF DIABETES 
         
In the  present study, duration of the diabetes in the group belonged 
maximum to less than 1 year(28.6%) and >5years (28.5%). 
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FIG.21 : FAMILY HISTORY 
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In the present study family history was positive in 65.7% of the 
patients indicating the influence  of genetic factors .The individuals who 
served as controls have equally significant positive family history and a 
chance of developing the disease. 
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DRUG INTAKE: 
TABLE – 12 :  DRUG INTAKE 
DRUGS PATIENTS 
Insulin and Oral hypoglycemic agents 3 
NIL 0 
Oral hypoglycemic agents 31 
Oral hypoglycemic agents 1 
                              
In the present study most of the patients were in  oral 
hypoglycemic drugs mainly(88.57%). Others were given oral drugs  in a 
combination with insulin. 
 
FIG. 22 : DRUG THERAPY - PATIENTS 
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ANALYSIS OF COMORBID CONDITIONS: 
TABLE - 13 
COMORBID CONDITION NUMBER OF PATIENTS 
Vascular diseases  1 
Hypothyroidism 3 
Osteo-arthritis    1 
Hypertension 8 
Peripheral neuropathy 1 
Pedal edema 1 
Nil 20 
 
FIG.23 - VARIOUS ASSOCIATED COMORBIDITIES - CASES 
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 In the present study overall comorbidity was seen in 42.85% of 
cases. Of them hypertension was found to be the most common 
associated comorbidity(22.8%) followed by hypothyroidism. 
ANALYSIS OF BMI : 
 In the present study analysis of BMI was done in every patient and 
risk factor assessed. Most of the patients (45.71%) were found to be in 
the category of over weight 
TABLE – 14 : BMI 
BMI NUMBER OF PATIENTS 
21-25(NORMAL) 9 
26-30(OVER WEIGHT) 16 
>30(OBESE) 10 
 
FIG.24 : BODY MASS INDEX IN PATIENTS 
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ANALYSIS OF LIPID PROFILE : 
In the present study an analysis of lipid profile was made  
CHOLESTEROL LEVEL NUMBER OF PATIENTS 
< 200(DESIRABLE) 19 
>200 TO 239(BODERLINE) 8 
>240  (UNDESIRABLE) 8 
 
TABLE .15 : CHOLESTEROL LEVELS 
FIG.25 : CHOLESTEROL LEVELS 
 
When the total cholesterol levels were analyzed, half of the patients 
(54%) were found to have a normal range. 22.85 % had their cholesterol 
levels in the high risk range. 
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TGL ANALYSIS :  
TGL NUMBER OF 
PATIENTS 
PERCENTAGE 
50 TO 160 (NRL) 22 62.85 
>160(ABNRL) 13 37.15 
 
TABLE : 16  - TGL -CASES 
62.85% of the patients were found to have TGL in the normal 
range. 
LDL ANALYSIS: 
TABLE - 17  : LDL LEVELS 
LDL 
NUMBER OF 
PATIENTS 
PERCENTAGE 
< 130 (NRL) 21 60 
130 TO 160(LOW RISK) 6 17 
>160 (HIGH RISK) 8 23 
 
LDL levels  were  found to be  abnormal in 40% of the patients. 
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HDL ANALYSIS : 
TABLE – 18 : HDL LEVELS 
HDL 
NUMBER OF 
PATIENTS 
PERCENTAGE 
>60 (DESIRABLE) 1 3 
>30 - 60(BODERLINE) 29 83 
< 30 (UNDESIRABLE) 5 14 
 
FIG .26 -  HDL CHOLESTEROL LEVELS 
 
 However HDL were found to be in the borderline for most of the 
patients(83%). 
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HDL/CHOLESTEROL RATIO ANALYSIS : 
TABLE : 19 - HDL/CHOLESTEROL RATIO 
HDL/CHOLESTEROL 
NUMBER OF 
PATIENTS 
PERCENTAGE 
NO RISK  > 37 2 5.7 
LOW RISK  - 19 TO 36 17 48.6 
HIGH RISK – 7 TO 18 16 45.7 
  
Most of the cases were found to be in the low risk (48.6%) & high 
risk (45.7%) category in relation to HDL/CHOLESTEROL ratio. 
 
Fig. 27 - HDL/TOTAL CHOLESTEROL- Risk attribution 
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ANALYSIS OF CONTROLS 
All the controls were analyzed for all the parameters as that of 
cases. 
DISTRIBUTION OF AGE 
 In the control group most of them belonged to the age group of 30-
50 years. 
TABLE – 20 : AGE DISTRIBUTION 
Age in years No. of patients 
0-20 0 
20-30 5 
30-40 8 
40-50 10 
50-60 5 
>60 7 
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FIG.28 :  AGE DISTRIBUTION 
 
SEX DISTRIBUTION: 
TABLE : 21 - SEX DISTRIBUTION 
SEX NUMBER OF PATIENTS 
MALE 9 
FEMALE 26 
 
 In the present study females constituted 74% of the total control 
population. 
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FIG. 29  - SEX RATIO – CONTROL GROUP 
ANALYSIS OF FAMILY HISTORY: 
TABLE - 22 : POSITIVE FAMILY HISTORY 
FAMILY HISTORY NUMBER OF PATIENTS 
PRESENT 21 
ABSENT 14 
 
FIG - 30 :   FAMILY HISTORY 
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In the present study family history was positive in 60% of controls. 
The other parameters like pulse rate, blood pressure, BMI, lipid 
profile were normal in case of controls. The associated co morbidities 
was only hypothyroidism in 3 cases of controls. The glycemic indices like 
serum fructosamine, nailfructosamine, HbA1C were also normal in these 
individuals. A minimal overlap is also noticed in nail and serum 
fructosamine. 
COMPARISON OF CASES AND CONTROLS: 
 
FIG.31.  AGE IN YEARS –COMPARISON OF MEANS 
The mean age of the case and control group were 51.11 and 41.54 
respectively. The range is between 22 and 72 for cases . The range for 
controls is 28 –72. Females formed the predominance of study group in 
both cases and controls.                                                                                                           
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FIG.32 : GENDER DISTRIBUTION 
                              
Both group had proportionately similar family history of ≥ 60% 
with no significant difference. 
TABLE - 23 : FAMILY HISTORY 
FAMILY HISTORY 
 
Total CONTROLS PATIENTS 
 
 
 
 
 
 
 
NIL  14 12 26 
   40.0% 34.3% 37.1% 
POSITIVE  21 23 44 
 
 
P value 
 60.0% 
 
0.621 
65.7% 
 
62.9% 
 
                             
SIGNIFICANCE 
    
  NIL   
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FIG – 33 :  FAMILY HISTORY 
 
 There is no significant difference in positive family history 
between patients and controls. 
COMRBID CONDITIONS 
The most common co-morbid condition  in the patients was 
hypertension while in control group there was no significant associated 
co- morbidity except for hypothyroidism. 
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TABLE – 24 :  COMPARISON OF CO-MORBID CONDITIONS 
CO-MORBID CONDITION 
 
Total CONTROLS PATIENTS 
 HYPERTENSION  3 8 11 
  8.6% 22.9% 15.7% 
HYPERTENSION & 
CORONARY DISEASE 
 0 1 1 
  0.0% 2.9% 1.4% 
HYPERTENSION & 
ARTHRITIS 
 0 1 1 
  0.0% 2.9% 1.4% 
NO CO-MORBID  31 21 52 
  88.6% 60.0% 74.3% 
ARTHRITIS  1 1 2 
  2.9% 2.9% 2.9% 
PEDAL EDEMA  0 1 1 
  0.0% 2.9% 1.4% 
PERIPHERAL 
NEUROPATHY 
 0 1 1 
  0.0% 2.9% 1.4% 
PULMONARY 
TUBERCULOSIS 
 0 1 1 
  0.0% 2.9% 1.4% 
     
    
 
 
The overall co-morbidity is 40% in patients and 11.4% in controls. 
BODY MASS INDEX:  
The average BMI of the case group was 27.1 (overweight) while 
that of controls was 25.4 ( normal range),  however the difference was 
weakly significant.(p value 0.09) 
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FIG.34 : BMICOMPARISON 
 
COMPARISION OF LIPID PROFILE : 
The lipid profile was done for each group and the results were 
analysed. The mean value for cholesterol in cases and controls were 196 
and 185 respectively. There was no significant difference between the 
two groups (p value 0.337). 
 
FIG. 35- COMPARISON – CASES AND CONTROLS – TOTAL 
CHOLESTEROL 
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HDL   CHOLESTEROL :  
          The HDL level of both groups were compared. The mean HDL 
levels of each group was 38.97 and 36.89. Though there was no 
significant difference between both groups, their levels were in the 
borderline risk range.(30-60) 
Fig. 36  :  HDL  CHOLESTEROL  COMPARISON CASE AND 
CONTROLS 
            
 HDL/CHOLESTEROL RATIO : The above ratio  was 21 and 
21.17 in cases and controls respectively. In both groups the mean value 
was found to be in the low risk group. Also no significant difference was 
noted in HDL values between cases and controls. 
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Fig .37 :  HDL / TOTAL CHOLESTEROL 
 
THE GLYCEMIC INDICES: 
COMPARING THE MEANS: 
 FASTING BLOOD SUGAR:  FBS            
FIG .38 :  COMPARISON OF FBS MEAN 
 
      HDL /TOTAL CHOLESTEROL 
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The difference is significant. 
 
FIG. 39 :  AVERAGE DERIVED GLUCOSE - MEAN 
 
FIG.40 :  HBA1C – MEAN 
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Fig.41 :  SERUM FRUCTOSAMINE MEAN 
 
Fig.42 :   NAIL FRUCTOSAMINE MEAN 
 
       NAIL FRUCTOSAMINE 
         SERUM FRUCTOSAMINE 
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TABLE - 25 : COMPARISON OF MEANS – GLYCEMIC INDICES 
S.NO VARIABLE MEANCONTROLS 
PATIENTS 
Mean 
PATIENTS 
T 
value 
P value Significance 
1 FBS MEAN 97.2 170.24 -
8.967 
0.0001 Strong 
significance 
2. MEAN BLOOD 
GLUCOSE 
100.77 202.17 -
8.388 
0.0001 Strong 
significance 
3. HbA1C 5.583 7.806 -
8.632 
0.0001 Strong 
significance 
4. SERUM 
FRUCTOSAMINE 
267.43 333 -
5.562 
0.0001 Strong 
significance 
5. NAILFRUCTOSAMINE 2.177 2.679 -
2.706 
0.009 significant 
 
ANALYSIS OF GLYCEMIC STATUS OF CASES AND 
CONTROLS: 
The set of initial and final values of patients were compared . 
Both show a decrease in the mean indicating a glycemic control 
has been achieved. 
Also the results well correlate with Fasting blood glucose and 
serum fructosamine levels. 
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FIG. 43  - INITIAL AND FINAL VALUES – HBA1C 
 
FIG. 44  - INITIAL AND FINAL VALUES – ESTIMATED 
AVERAGE GLUCOSE 
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The initial and final values of nail fructosamine in patients also 
indicate that glycemic control is achieved and was lower compared to 
initial values and hence the assay is comparable to other glycemic 
indices. 
 
FIG.45- INITIAL AND  FINAL VALUES – NAIL 
FRUCTOSAMINE 
NAIL FRUCTOSAMINE VERSUS HbA1C: 
The following figure show the linear relationship between nail 
fructosamine and Hemoglobin A1C. 
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FIG.46 -  INITIAL AND FINAL VALUES NAIL& HBA1C 
COMPARED 
 
TABLE – 26 : PAIRED SAMPLES  T-  TEST: 
VARIABLES 
 Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
TREND 
INITIAL -
FINAL 
t 
value 
 
SIGNIFICA
NCE 
INITIAL 
FINAL 
 
HbA1C 
 
8.654 2.1203 .3584 DECREASI
NG 
3.701 0.001 
HbA1C 
 
 
7.81 1.480 .250  
 
 
  
INITIAL 
FINAL 
MBG 202.17 70.742 11.958 DECREASI
NG 
3.721 0.001 
MBG 
 
 
173.80 49.282 8.330    
INITIAL 
 
 
FINAL 
Nail 
fructosami
ne 
3.1017 1.39401 .23563 DECREASI
NG 
1.695 0.09 
Nail 
Fructosam
ine 
2.6786 .90304 .15264    
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HbA1C and nail fructosamine show significance and the values are 
0.001 and 0.009 respectively. 
PEARSON’S CORRELATION: 
As per the aim of the study, the correlation of nail fructosamine to 
HemoglobinA1C is performed using PEARSON’S CORRELATION. 
The results are as follows: 
TABLE : 27 
Correlations 
 
HbA1
C1 
HbA1
C2 
Nailfru
ct1 
NailFru
ct2 
HbA1C1 Pearson Correlation 1 .772
**
 .068 -.107 
Sig. (2-tailed)   .000 .696 .541 
HbA1C2 Pearson Correlation .772
**
 1 .039 .038 
Sig. (2-tailed) .000   .822 .831 
     
Nailfruct1 Pearson Correlation .068 .039 1 .229 
Sig. (2-tailed) .696 .822   .186 
     
NailFruct2 Pearson Correlation -.107 .038 .229 1 
Sig. (2-tailed) .541 .831 .186   
     
**. Correlation is significant at the 0.01 level (2-tailed).  
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The values are 0.068 and 0.038 for the initial and final set of values 
and weakly correlated. 
COMPARISON OF INDIVIDUAL GROUPS - GLYCEMIC 
CONTROL 
TABLE - 28  : HbA1C CUTOFFVALUE6.5% 
         HbA1C% 
 
Total CONTROLS PATIENTS 
 <6.5  35 8 43 
  100.0% 22.9% 61.4% 
 
>6.5 
 0 27 27 
  0.0% 77.1% 38.6% 
 
 
FIG.47 : HBA1C VALUES BELOW AND ABOVE CUTOFF 
VALUE – 6.5% 
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FREQUENCY BELOW AND ABOVE PHYSIOLOGICAL RANGE 
(2.5 µmol)  
TABLE.29 : NAIL FRUCTOSAMINE 
NAIL FRUCTOSAMINE 
µmol/g 
 
Total CONTROLS PATIENTS 
 <2.5  24 18 42 
  68.6% 51.4% 60.0% 
>2.5  11 17 28 
  31.4% 48.6% 40.0% 
 
 
FIG : 48 - NAIL FRUCTOSAMINE BELOW AND ABOVE CUT 
OFF VALUE 2.5µMOL 
 
        NAILFRUCTOSAMINE  
NAILFRUCTOSAMINE 
FRFRUCTOSAMINE 
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TABLE – 30 : SERUM FRUCTOSAMINE: 
SERUM 
FRUCTOSAMINE 
 
Total CONTROLS PATIENTS 
 <285µmol  22 7 29 
 62.9% 20.0% 41.4% 
 
 
>285µmol 
  
13 
 
28 
 
41 
 37.1% 80.0% 58.6% 
 
 
FIG.49 :  SERUM FRUCTOSAMINE VALUES ABOVE AND 
BELOW CUT OFF 285µMOL 
There is an overlap seen in  the glycemic indices, more in nail 
fructosamine and serum fructosamine as seen in other studies. 
    SERUM FRUCTOSAMINE 
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RECEIVER OPERATING CHARECTERISTIC CURVE 
ANALYSIS: 
NAIL FRUCTOSAMINE ASSAY: 
 
FIG.50 : RECEIVER OPERATING CHARECTERISTIC CURVE 
         Analysis of the ROC curve showed area under the curve of 0.674 
(95%Confidence interval of 0.539 – 0.809 and a cut- off point of 
2.35µmol/g equivalent of nail.) p value of 0.015) with a sensitivity 
59.3% and specificity 58.1%  
      NAIL   FRUCTOSAMINE    ASSAY 
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The  individual values ( 56)  of the two glycemic indices were 
comparable and show linear relationship except for four patients. 
Two were hypothyroid, on eltroxin, one patient on treatment for 
schizophrenia and the other was taking aspirin for treatment of cerebro -
vascular complication. 
Thus an evaluation for confounding factors in the assay due to 
alcohol consumption, commonly used drugs and other substances will 
enlighten  us on further implication of this assay. 
REGRESSION ANALYSIS (LEAST SQUARES METHOD) 
 
FIG.51 : CORRELATION – NAIL FRUCTOSAMINE & HBA1C 
CONTROLS   R VALUE >0.5 LINEAR 
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FIG. 52 :  CORRELATION NAIL FRUCTOSAMINE AND HBA1C 
–CASES -LINEAR 
 
FIG.53 : CORRELATION NAIL FRUCTOSAMINE AND 
FASTING BLOOD GLUCOSE LINEAR - CONTROLS 
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FIG.54 : CORRELATION GRAPH NAIL FRUCTOSAMINE AND 
FASTING BLOOD GLUCOSE – PATIENTS LINEAR 
 
FIG .55 :   NAIL FRUCTOSAMINE AND SERUM 
FRUCTOSAMINE – CONTROLS LINEAR. 
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FIG.56 :  NAIL FRUCTOSAMINE  AND SERUM 
FRUCTOSAMINE – CASES - LINEAR 
The  r values are well correlating for nail fructosamine and serum 
fructosamine in patients and controls than for HbA1C and fasting blood 
glucose by the least squares regression analysis. 
 101 
DISCUSSION 
Analysis of the results : 
1. The glycation in nail protein which forms 80%  of the nail tissue 
depends on the  blood glucose levels of the individual and reflects 
the average blood glucose over the preceding three months ie the 
duration of the nail growth across the nail plate. Hence it is 
compared with HbA1C which also reflects the average glucose 
over the same duration. 
2. Out of the 70 individuals analyzed  , 35 are known diabetics and 35 
are healthy non-diabetic subjects of the same age group,whose 
Fasting Plasma Glucose is <126 mg %. 
 
3. The observations made are: 
a)  Glycemic status analysis. 
b) The risk factor analysis  
 
1. Glycemic status of the individuals is studied by 
comparison of Fasting blood Glucose, HbA1C, Serum 
Fructosamine with nail fructosamine for all patients and 
compared with control population. 
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2. The relationship of the nail fructosamine with FBS is 
linear. 
3. The relationship of nail fructosamine and HbA1C is 
linear. 
4. The relationship of nail fructosamine and serum 
fructosamine is linear. 
5. As observed by A.S. Kishabongo et al (2013)(REF) the 
ROC analysis for nail fructosamine yielded a cut off  
value  of 3.14 μmol/g of nail ,but  in this assay ,it was 
found to be 2.35μmol/g of nail, the reason  could be the 
smaller sample size. 
6. The mean for diabetics and control population studied 
were 3.1 and 2.18μmol/g respectively in the initial 
readings taken . 
7. As the aim of the study was to detect the glycemic control 
achieved the repeat values for the same individuals were 
done after 10 - 12 wks  and the mean for the final values 
was 2.68μmol/g .This reflects the  glycemic control 
achieved during the period of study. The same finding is 
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also confirmed by the mean values obtained in Hb A1C 
(figure 43 to 46)  initial and final. 
8. Both initial and final values in the nail fructosamine were 
found to be above the physiological range  2.0 - 2.5μ  mol 
fructosamine / gm of protein, as observed by Goldsmith , 
whereas the control group mean lies within the 
physiological range.(2.18μ  mol) 
9. The mean values of controls as compared to the values 
given by Kishabongo et al (1.75 μmol) done in the sub-
Saharan African population is less than that done in our 
south Indian population because the staple food varies 
between these two countries. The following figure 
clarifies  this issue, the reasons being the staple cereal is 
maize in sub-Saharan region (glycemic index 55) but for 
the population in this study is rice (glycemic index varies 
from 86 -109 depending upon the variety of rice). 
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10.DATA FROM THE REPORT OF CCAFS 
 (Climate Change Agriculture and Food Security) 
 
 
FIG.57 : FOOD CONSUMPTION DATA – SOUTH ASIA 
The cereal consumption is more in proportion to the total food 
intake in south Asian population and rice being the staple food. 
 
 
FIG.58 :  SUB – SAHARAN AFRICA – DIET PATTERN 
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11. The cereal consumption is less in proportion to the 
total food intake. The roots and tubers taken in greater 
proportion are rich in fibre These food habits are 
possible reasons for the lower mean value for nail 
fructosamine in control population in the sub-Saharan 
region. 
12. Also the population included for study as per the sub - 
Saharan study were aged 1 - 91 years  and mean for 
controls is 36 yrs and for diabetics 62 yrs .Considering 
the median for diabetics without complications in the 
literature referred,it was 3.77μmols. In our study mean 
age for controls is 41.54 and cases is 51 yrs.  
The values are less in our study group because of the difference in 
age and duration of the diabetes . 
13. Both nephropathy and retinopathy were excluded from 
our study. The individuals with nephropathy and 
retinopathy were included  in the sub Saharan study 
and their median nail fructosamine values were in the 
higher range 5.64 and 5.65μmol/g of nail.  
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4. The nail fructosamine assay is easier, simpler and cost effective. 
 
5. The sample collection can be done by the patients themselves or by 
their relatives. Sample collection is easier and do not need 
technical personnel. 
6. Transport and preservation of sample is easier. 
7. The sample is stable for >3 weeks. 
8. Pre-analytical variation is practically ―NIL‖ 
9. The  sample could be collected non- invasively. The fear of needle 
prick alleviated and the pain can be avoided .It is useful for the 
patient’s long term follow up. 
10. The procedure is simple to perform and can be performed in any 
clinical laboratory  with basic equipments. (spectro photometer) 
11. The precision of the assay is good. 
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CONCLUSION 
On comparing with other glycemic indices like fasting plasma 
glucose, serum fructosamine and HbA1C, nail fructosamine shows linear 
relationship. 
Interference in the assay due to commonly used drugs has to be 
evaluated and then the procedure can be standardized for routine use in 
the laboratory to assess glycemic status of the individuals  both diabetic 
and non- diabetic individuals. 
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SUMMARY 
A study was conducted in Government Stanley Medical College 
and Hospital. In the Department of Biochemistry, titled glycated nail 
protein as an indicator of long term glycemic control. 
A total of 70 individuals, 35 known diabetic patients and 35 
healthy individuals were enrolled for the study. The patients were 
longitudinally followed up for three months to assess their glycemic 
status. 
The aim was to establish whether the nail fructosamine could be 
used to determine the glycemic status of the diabetic patients over the 
preceding three months which is the turnover time of the nail from root to 
the free edge.The Hemoglobin A1C estimation in the same patients at a 
same time was used to confirm the changes in the patient’s glycemic 
status and compared with nail fructosamine. A linear relationship was 
established after analysis of the results. 
The fasting blood glucose and serum fructosamine were also 
measured for assessing the blood glucose levels. These parameters on 
comparison with nail fructosamine showed linear relationship. 
No interference was done in the treatment schedule of the patients. 
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Also the risk factors like positive family history, blood pressure, 
BMI, lipid profile, were also analysed. Results showed  only moderate 
increase in risk factors among patients than controls. 
To conclude the nail fructosamine assay could be standardized for 
testing the levels of blood glucose over the previous three month’s 
duration. 
 The reference range in south Indian population needs to be 
established. 
The interference like drugs and other dietary substances which 
might react with nitrobluetetrazolium need to be studied and the 
procedure can be used as routine laboratory investigations to assess the 
blood glucose levels on long term basis. The method is cheaper , easier to 
perform and sample collection and preservation is easier (nail clippings 
form finger nails). 
Pre analytical variation of the analyze as observed with other 
analyzes is practically nil. 
Cost of testing is less compared to other indices. Precision  of the 
assay is good. CV Calculated was 7.8% 
SI.
No Age Sex Duration
Family 
H/o
Treatme
nt
Comorb
id Height cm
Weight 
Kg
PR / 
mt
Bpmm 
Hg
Gr. 
Prturia
Ptnemi
a
Urine 
PCR Urea
Creatinin
e
Choles
ter TGL
HD
L LDL VLDL
FBS 
Mean MBG-1
HbA1C 
1
MBG-
2
HbA1C-
2
Nailfruc
t1 SrFruct1
NailFruct
2
Protei
n Alb Hb% BMI
1 66 F 7yrs FMB IN+OHA Nil 156 66 82 150/70 Nil Nil 0.1 18 0.4 250 208 40 168 42 171.5 224 9.3 234 9.6 2.27 308 4.3 5 3 10.3 27
2 49 M 5mo nil OHA Nil 168 72.5 78 150/80 nil nil 0.02 24 0.6 114 178 40 38 36 199 217 9.1 177 7.9 4.3 437 3 5 2.3 14.4 25.7
3 56 F 7mo nil OHA Nil 159 60.4 82 140/70 Nil Nil 0.02 16 0.9 186 126 58 103 26 159 194 8.4 194 8.4 2.6 352 4.8 5 3 12 23.9
4 50 F 3mo Nil OHA Nil 158.5 62.7 72 110/60 Nil Nil 0.07 24 1 166 104 62 83 20 143 170 7.7 127 6.4 3.2 334 2.6 7 3.5 12 25.1
5 52 M 3yrs F OHA HTCVA 161 78.3 78 110/70 Nil Nil 0.04 20 1.1 100 178 30 35 36 164 254 10.2 270 10.7 2.1 361 2.2 8 3.8 13 30.2
6 61 F 8yrs FBGf OHA HT 153 42.6 92 120/60 Nil Nil 0.05 24 0.9 206 128 44 134 56 128 147 7 154 7.2 1.5 289 1.7 7.5 3.1 11.3 18.2
7 48 F 0.6yrs nil OHA Nil 158 65.6 86 130/80 Nil Nil 0.025 24 0.8 172 368 44 41 70 285 294 11.4 274 10.8 1.6 423 3.1 8 3.5 11 26.3
8 40 F 1yr F IN+OHAHypoTh 151 74 72 130/90 Nil Nil 0.24 26 0.6 172 258 44 77 52 134 144 6.9 134 6.6 2.2 285 3 8 2.8 10.8 32.4
9 49 F 4yrs FM IN+OHA Nil 143 53.6 86 120/80 Nil Nil 0.05 20 0.4 165 134 38 264 101 295 334 12.6 257 10.3 4.2 331 2.5 7.8 4.2 11.7 26.3
10 43 F 12yrs BS OHA Nil 146 42.3 82 110/70 Nil Nil 0.02 28 1 260 144 52 184 28 182 207 8.8 164 7.5 3.8 408 3.4 5.1 3.1 9.2 19.9
11 61 F 10yrs M OHA HypoTh 160 84 76 120/70 nil Nil 0.12 28 0.3 212 123 26 160 28 244 260 10.4 214 9 7.5 217 1.9 8.2 3.3 13.4 32.9
12 67 M 22yrs F OHA nil 167 61 82 130/90 nil Nil 0.09 30 0.6 204 156 46 127 28 156 180 8 167 7.6 4.4 370 2.2 8.3 4.6 12.8 21.9
13 67 F 12yrs nil OHA nil 148 59.3 70 90/60 Nil Nil 0.1 32 0.8 178 100 54 138 20 112 204 8.7 154 7.2 2 309 1.9 8 4.8 11.6 27.1
14 45 F 4yrs Gm OHA PE 159.5 73.3 88 120/70 Nil Nil 0.093 26 0.5 198 146 22 145 30 217 270 10.7 227 9.4 4.9 380 3 7.5 3 12.4 29
15 45 F 4yrs B OHA HypoTh 153 71.3 72 100/70 Nil Nil 0.16 24 0.8 118 156 22 66 28 167 157 7.3 130 6.5 2.74 227 2.2 5.9 3 10.7 30.5
16 63 F 12yrs nil OHA OA 143.5 65.9 74 120/60 Nil Nil 0.05 20 0.9 286 144 42 212 28 138 167 7.6 137 6.7 4.4 374 3.9 6.7 3.8 11.5 31.8
17 51 F 1Yr M OHA PT 143 60 96 130/80 nil nil 0.08 25 1 168 142 30 91 30 169 250 10.1 207 8.8 2.5 341 1.6 8 4.5 13.4 29.4
18 40 F 1.5yrs M OHA nil 150 71 82 130/80 nil nil 0.03 31 1 196 180 42 118 36 147 177 7.9 160 7.4 1.4 322 1.2 7.9 4.3 13.1 31.5
19 40 F 3yrs C oha nil 165.5 8.5 80 120/80 nil nil 0.05 30 0.8 140 265 38 49 54 232 284 11.1 250 10.1 2.7 403 1.8 7.7 3.9 9 30.9
20 50 F 2yrs nil OHA HT 152 59 72 130/80 Nil Nil 0.03 24 0.9 280 298 44 86 60 171 197 8.5 190 8.3 2.1 249 1.8 5.1 2.9 9.4 25.5
21 42 F 1 yr M OHA HT,OA 145 72 84 130/80 Nil Nil 0.04 20 0.9 140 256 38 52 52 120 117 6.1 114 6 1.6 280 2.1 6.5 3 12 34.3
22 55 M 6yrs F OHA Nil 156 48 80 110/70 Nil Nil 0.07 23 0.6 210 315 20 130 63 132 124 6.3 120 6.2 6.2 237 2.9 7.7 3 14.1 19.8
23 55 F 1.5yrs F,D OHA Nil 146 55 82 110/70 Nil Nil 0.5 28 1.1 244 130 42 176 26 130 130 6.5 107 5.8 3.8 325 2.2 8 4.5 10.9 25.8
24 57 F 6yrs nil OHA HT 146 67 82 110/70 Nil Nil 0.052 35 1.2 150 136 22 100 28 220 274 10.8 220 9.2 2.5 369 1.8 7.8 4.7 12.8 31.5
25 34 M 0.5yrs F OHA Nil 155 69 96 130/80 Nil Nil 0.5 24 0.7 174 134 42 105 26 175 294 11.4 250 10.1 3.7 353 2.9 5 3.3 12.5 28.8
26 38 M 0.5yrs SB OHA Nil 164 58 86 130/80 Nil Nil 0.03 20 0.8 214 105 46 147 28 196 417 15.1 174 7.8 2.3 379 2.2 5.3 2.7 12.8 21.6
27 69 F 6yrs S OHA HT, CAD 160 64 84 140/80 Nil Nil 0.05 26 0.6 204 160 36 116 52 150 157 7.3 170 7.8 2.7 322 4.7 7 3.5 11.2 25
28 47 F 0.5 yrs B OHA Nil 154 63 84 110/80 Nil Nil 0.4 20 0.8 218 156 30 157 32 124 120 6.2 114 6 1.4 295 2.3 6 4 12 26.6
29 57 M 0.5yrs nil OHA Nil 155 60 72 110/70 Nil Nil 0.36 26 0.9 256 120 39 193 40 137 117 6.1 110 5.9 2.7 234 1.9 6 3.2 13.2 25
30 22 F 0.5 yrs B OHA Nil 140 65 82 120/70 Nil Nil 0.02 24 0.7 300 196 44 216 40 251 220 9.2 140 6.8 2.8 414 3.2 5.5 3 10.4 33.1
31 66 M 4yrs nil OHA HT 161 64 80 140/90 Nil Nil 0.03 18 0.6 210 261 34 124 52 153 140 6.8 134 6.6 3 304 2.9 5.3 3 12.3 24.7
32 61 F 6yrs nil OHA Nil 150 58 86 130/80 Nil Nil 0.05 22 0.6 298 158 39 228 48 125 147 7 154 7.2 5.5 356 4.6 7.5 3.2 13 25.8
33 42 M 4yrs F OHA Nil 153 58 84 130/80 Nil Nil 0.01 25 0.8 176 190 38 102 38 154 224 9.3 177 7.9 3 368 2.7 6 3.6 12.5 24.8
PATIENTS
34 47 F 7yrs F OHA PN 146 63 74 120/70 Nil Nil 0.03 29 1 166 178 36 95 36 167 140 6.8 154 7.2 2.65 295 2.75 5.3 3 9 29.6
35 54 F 0.5yrs nil OHA Nil 146 54 76 120/70 Nil Nil 0.02 30 1 130 156 40 60 32 111 124 6.3 124 6.3 2.3 404 2.4 5 3.5 11.5 25.4
HDLCH
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9
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1
14
15
15
16
13
21
PATIENTS
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PROFORMA 
 
HbA1C Vs NAIL FRUCTOSAMINE                              
Department of Biochemistry  Stanley Medical College, Chennai. 
 
Name:   Age:                   Sex:              ID No:               Date: 
 
OP No:                                           Type of Diabetes:                                      
Positive Family History        
 
Address:                                        Duration:                                          Type: 
 
Drugs:                       
 
Metformin:                         Glipizide:                       Glibenclamide:                          
 
Others: 
 
Insulin dose:                                Duration :                                  
 
Co-morbid illness:                               
 
HT/CAD/ Nephropathy/Neuropathy/Thyroid disorders/ Cataract/Surgeries 
underwent 
 
Examination: 
General          PR                            BP   System: 
CVS:     RS:                                         CNS:                  ABD: 
Others: 
Diagnosis: 
Routine Investigations: 
Urine:                        Alb:                 Sug:                 Creat: 
Blood:                       Hb%                 Cell count: 
Urea:                        Creat:                Gluc:                   Protein:                               
Alb:                   A/C ratio 
Chol:                        TGL                     HDL                              ECG: 
HbA1C MBG FBSM SFM NF 
     
S.No Date HbA1C MBG FBG-M SF NF 
I       
II       
III       
IV       
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